

## CIRCULAR 14 of 2022

Date: 16 September 2022

To: All applicants

### RE: IMPLEMENTATION PLAN FOR RE-REGISTRATION OF HUMAN ALLOPATHIC MEDICINES

---

This circular serves to inform applicants, manufacturers and principals the implementation plan for re-registrations (marketing authorization renewals). The requirement for re-registrations was communicated in the MCAZ circular 3 of 2022 (point 6) dated 17 February 2022. With effect from 1 January 2023, product registrations for human allopathic medicines will have a validity period of five (5) years. Applications for re-registration would therefore need to be submitted every five (5) years in order to maintain the products on the MCAZ register.

The process of re-registration will be applicable to all human allopathic medicines registered by MCAZ. The process will be carried out as follows:

1. Products registered from the 1<sup>st</sup> of January 2023

With effect from 1<sup>st</sup> January 2023, all new registrations will have a validity period of 5 years from the date of registration. The validity period will be indicated on the registration certificate. An application for re-registration of the product should be submitted before the validity period of the product expires and can be submitted 3 months before the re-registration date.

2. Products registered prior to the 1<sup>st</sup> of January 2023

Registration of all products registered before 1<sup>st</sup> January 2023 will expire on the 31<sup>st</sup> of December 2027. Applications for re-registration of these products can be submitted from the 1<sup>st</sup> of January 2023 to the 31<sup>st</sup> of September 2027. A validity period of 5 years from the date of re-registration will be indicated on the registration certificate.

In both cases, applications for re-registration of the product should be submitted before registration expires. In the case where the applicant does not submit an application for re-registration 3 months after expiry, product registration will be cancelled.

The following should be considered when making an application for re-registration:

1. The submission should be made in CTD format
2. The re-registration process should be in-line with the MCAZ guideline on product re-registrations.
3. Post approval variations to the products dossier will not be accepted at the time of re-registration. Applications for the post variations should be made separately.

Please note that the re-registration process does not replace the process of annual retentions. No processing fees will be charged for re-registrations. Requests for exemptions to any of the requirements should be submitted before the re-registration dates and will be considered on a case-by-case basis.

Yours faithfully,

**MEDICINES CONTROL AUTHORITY OF ZIMBABWE**



.....  
R. T. RUKWATA (Mr)  
**DIRECTOR-GENERAL**